Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Articles online first > Minerva Endocrinology 2021 Apr 01

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Endocrinology 2021 Apr 01

DOI: 10.23736/S2724-6507.21.03378-2

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

FGF23 functions and disease

Cristiana CIPRIANI , Salvatore MINISOLA, Luciano COLANGELO, Viviana DE MARTINO, Federica FERRONE, Federica BIAMONTE, Vittoria DANESE, Chiara SONATO, Rachele SANTORI, Marco OCCHIUTO, Jessica PEPE

Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy


PDF


The main function of fibroblast growth factor 23 (FGF23) is the regulation of phosphate metabolism through its action on the sodium-dependent phosphate cotransporters in the proximal renal tubules. Additionally, FGF23 interacts with vitamin D and parathyroid hormone in a complex metabolic pathway whose detailed mechanisms are still not clear in human physiology and disease. More recently, research has also focused on the understanding of mechanisms of FGF23 action on organs and system other than the kidneys and bone, as well as on its interaction with other metabolic pathways. Collectively, the new evidence are successfully used for the clinical evaluation and management of FGF23-related disorders, for whom which new therapies with many potential applications are now available.


KEY WORDS: FGF23; Phosphate; Physiology; Pathophysiology

inizio pagina